Immutep Ltd (IMM)

0.390
+0.010(+2.63%)
  • Volume:
    186,740
  • Bid/Ask:
    0.385/0.390
  • Day's Range:
    0.385 - 0.395

IMM Overview

Prev. Close
0.38
Day's Range
0.385-0.395
Revenue
330K
Open
0.385
52 wk Range
0.305-0.725
EPS
-0.03
Volume
186,740
Market Cap
333.11M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,557,232
P/E Ratio
-
Beta
1.79
1-Year Change
-17.98%
Shares Outstanding
854,122,801
Next Earnings Date
31 May 2022
What is your sentiment on Immutep?
or
Vote to see community's results!

Immutep Ltd News

Immutep Ltd Company Profile

Immutep Ltd Company Profile

Employees
0
Market
Australia

Immutep Limited is an Australia-based biotechnology company. The Company is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The Company has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyBuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell